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Treatment Policy and Liver Histopathology
Predict Biliary Atresia Outcomes: Results after
National Centralization and Protocol Biopsies
Maria Hukkinen, MD, PhD, Anna Kerola, MD, Jouko Lohi, MD, PhD, Päivi Heikkilä, MD, PhD,
Laura Merras-Salmio, MD, PhD, Timo Jahnukainen, MD, PhD, Antti Koivusalo, MD, PhD,
Hannu Jalanko, MD, PhD, Mikko P Pakarinen, MD, PhDBACKGROUND: Different treatment policies can influence biliary atresia outcomes, but the pathophysiology
of expanding fibrosis occurring even after successful portoenterostomy remains unclear.
STUDY DESIGN: Clearance of jaundice (COJ) (bilirubin <20 mmol/L), native liver survival, and overall sur-
vival rates of biliary atresia patients were analyzed before and after national centralization
of management, as well as in relation to native liver histopathology of protocol biopsies.
RESULTS: Of the 59 patients, 35 were managed after centralization and received standardized postopera-
tive adjuvant therapy, including corticosteroids. After centralization, age at portoenterostomy
decreased from 73 days to 54 days (p ¼ 0.014) and COJ rate increased from 42% to 80%
(p ¼ 0.005), 5-year native liver survival increased from 38% to 70% (p ¼ 0.014), and 5-year
overall survival increased from 68% to 94% (p ¼ 0.007). High-grade portal inflammation at
portoenterostomy predicted COJ (odds ratio 3.66; p ¼ 0.011) and slower fibrosis progression
(b ¼ 0.74; p ¼ 0.005). Native liver survival was extended in patients with high-grade portal
inflammation (p ¼ 0.002) and in patients whose bilirubin normalized within 3 months (p <
0.001). Portal inflammation and cholestasis reduced only after COJ (p< 0.001), and persisting
ductal reaction, reflected by cytokeratin 7-positive proliferating bile ductules and periportal
hepatocytes, correlated with follow-up fibrosis (r ¼ 0.454 to 0.763; p < 0.001 to 0.003).
Cytokeratin 7 immunopositivity of periportal hepatocytes increased after COJ (p¼ 0.015) and
was the only predictor of follow-up liver fibrosis (b ¼ 0.36; p ¼ 0.002) in multiple regression.
CONCLUSIONS: Biliary atresia outcomes improved significantly after centralization and standardized management.
Resolution of cholestasis and reduction of high-grade portal inflammation postoperatively predict
slower fibrosis progression and improved native liver survival, and persisting ductal reaction parallels
progressive native liver fibrosis despite COJ. (J Am Coll Surg 2018;226:46e57.  2017 by the
American College of Surgeons. Published by Elsevier Inc. All rights reserved.)Disclosure Information: Nothing to disclose.
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All rights reserved.Biliary atresia (BA) is an idiopathic cholangiopathy of in-
fancy characterized by fibro-inflammatory obstruction of
extrahepatic bile ducts, leading to cholestasis and eventu-
ally cirrhosis.1 Adjacent to biliary fibrosis, chronic chole-
stasis promotes proliferation of bile ductules, called
ductal reaction.2 The first-line treatment for BA is por-
toenterostomy (PE), which typically restores adequate
bile flow in approximately half of patients.3-7 It remains
unclear why destruction of intrahepatic bile ducts, which
promotes progressive liver damage, continues after resolu-
tion of jaundice.8 Additional understanding of the patho-
physiology driving liver injury is essential for novel
approaches designed to extend native liver survival. Biliary
atresia is the most common indication for pediatric liverhttps://doi.org/10.1016/j.jamcollsurg.2017.09.009
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Abbreviations and Acronyms
BA ¼ biliary atresia
BASM ¼ biliary atresia splenic malformation
COJ ¼ clearance of jaundice
CK7 ¼ cytokeratin 7
HCM ¼ hepatocyte-cholangiocyte metaplasia
LT ¼ liver transplantation
OR ¼ odds ratio
PE ¼ portoenterostomy
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patients within 20 years of PE.9,10
After successful PE, plasma bilirubin levels normalize,
which postpones the need for LT and improves patient
survival.11,12 Portoenterostomy success rates are influenced
by several patient-dependent factors, such as age at oper-
ation,3,6,13 anatomy of the biliary tract remnant,13,14 coex-
istent congenital malformations,3,6,7 and liver histologic
features at PE, including degrees of fibrosis and ductal re-
action.15-18 Postoperative steroids can improve clearance of
jaundice (COJ) rates, although their effect on native liver
survival remains unestablished.19,20 In addition, hospitals
with low caseloads can have inferior outcomes compared
with more experienced centers,4,7,21 which has led to
centralization of BA treatment, at least in the UK and
Finland.4,21
After national centralization of BA management in
Finland to Helsinki University Children’s Hospital, re-
sults of the initial short-term follow-up demonstrated
significantly improved COJ and transplant-free survival
rates.4 To improve BA management and to better under-
stand the pathophysiology behind progressive liver dam-
age, protocol native liver biopsies at PE and during
follow-up were started after centralization.22 Here, we
evaluate the effect of centralization on BA outcomes after
more than a decade of follow-up and compare the out-
comes with those obtained in Helsinki before centraliza-
tion. In addition, we address predictors of COJ, native
liver survival, and overall survival, and analyze how liver
histopathology at PE and during follow-up relates to these
outcomes.METHODS
Ethics
This study was approved by the Ethical Committee of
Helsinki University Hospital and the Finnish National
Authority of Medicolegal Affairs and Health. A consent
from participants or their caregivers was obtained before
any procedures.Patients
In 2005, the Ministry of Health centralized BA manage-
ment in Finland from 5 university hospitals to Helsinki
University Children’s Hospital, which is a tertiary referral
center for pediatric liver diseases with a nationwide LT
program since 1987. All BA patients managed in Helsinki
during 1987 to 2016 with at least a 4-month follow-up
after primary operation were included. Biliary atresia
diagnosis was confirmed by operative findings; periopera-
tive cholangiography, when possible; and histopathologic
assessment of the biliary remnant. Medical records were
reviewed for gestational age and weight, associated
congenital malformations, anatomic type of BA,23 details
of operative management, COJ rate, LT listing and per-
formance, and possible death. Biliary atresia splenic mal-
formation syndrome (BASM) was defined as presence of
poly- or asplenia.24 Clearance of jaundice was defined as
serum total bilirubin <20 mmol/L at any time point post-
operatively. Bilirubin levels were recorded at 3 and 6
months after PE, as well as at last follow-up.
Management of biliary atresia
In contrast to the variable follow-up and medical manage-
ment practices performed before centralization, manage-
ment and follow-up of BA were standardized in 2005,
and a single team led by 1 surgeon operated on patients
thereafter. Ursodeoxycholic acid (30 mg/kg/d),
thrimetoprim-sulfadiazine (4 þ 12.5 mg/kg/d), and dexa-
methasone with decreasing doses (0.6 to 0.2 mg/kg/d,
days 5 to 28) were routinely administered postopera-
tively.25-27 Enteral energy provision was aimed at
150 kcal/kg/d with use of carbohydrate and medium
chain fatty acid energy supplements.28 Fat-soluble vitamin
supplements were continued after discharge together with
ursodeoxycholic acid and thrimetoprim-sulfadiazine.4,28
Follow-ups were arranged at 3-month intervals in local
hospitals and at least once a year in Helsinki.
Liver histology
Liver biopsies at PE and at last follow-up were analyzed
and the changes occurring in histology over time were
evaluated according to COJ status. Routine follow-up bi-
opsies were initiated in 2005 and performed 1, 5, and 10
years after PE or when clinically indicated. Follow-up bi-
opsies were taken percutaneously with ultrasound guid-
ance under general anesthesia for endoscopic variceal
surveillance.29 For patients who underwent LT, follow-
up liver histology was mainly based on the explant.
In addition to conventional stains, immunostaining for
cytokeratin 7 (CK7) was performed using a rabbit anti-
human monoclonal antibody and ultra View Universal
DAB Detection Kit (Ventana). Two experienced pediatric
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until consensus was reached. Specimens were analyzed for
portal inflammation (the extent of portal cellular infil-
trate, scored 0 to 3), intracellular, intracanalicular, and
ductal cholestasis (scored 0 to 3), and fibrosis (Metavir
stage 0 to 4).30 Ductal reaction was visualized by CK7
staining in proliferative bile ductules (scored 0 to 2) and
adjacent hepatocyte-cholangiocyte metaplasia (HCM) by
CK7 staining in periportal hepatocytes (scored 0 to
4).15,17,22 The changes of Metavir, CK7 immunostaining,
and portal inflammation scores between PE and follow-
up were calculated. Fibrosis progression rate (not calcu-
lated for patients with Metavir ¼ stage 4 at PE, n ¼ 7)
was defined as the change of Metavir score divided by
the years between PE and follow-up biopsies, and
expressed as change in Metavir score/year.
Statistical methods
Continuous data are expressed as median values with
interquartile ranges (IQR) and categorical data as fre-
quencies unless otherwise stated. Kruskal-Wallis and
Mann-Whitney U tests were used to compare indepen-
dent continuous variables, Wilcoxon signed-rank test to
compare repeated measurements, and Fisher’s exact test
to compare frequencies between groups. Associations be-
tween variables were examined with Spearman rank
correlation.
Predictors of COJ, bilirubin levels at 3 months after
PE, follow-up Metavir score, and fibrosis progression
rate were evaluated with regression analyses. For COJ,
odds ratios (OR) with 95% CIs were generated by binary
logistic regression, and linear regression was used for
continuous variables. Predictors showing significant asso-
ciations with outcomes variables in simple regression were
included in multiple regression analyses.
Cumulative native liver and overall survival rates were
analyzed with Kaplan-Meier curves. Univariate predictors
of survival were evaluated with the log-rank test. Multi-
variate survival models were performed by generating haz-
ard ratios with 95% CIs with Cox proportional hazards
regression model, adjusted for statistically significant vari-
ables from univariate models and for age at PE3,6,7 for
native liver survival. The level of significance was set at
p < 0.05 and all analyses were performed with SPSS,
version 24 (IBM Corp).RESULTS
Baseline characteristics
Altogether 63 patients were identified. Two patients were
excluded; 1 died of heart defect before operation and the
other with multiple severe anomalies died few weeks afterPE; no COJ status for him could be defined. The remain-
ing 61 patients were divided into cohorts A (n ¼ 25 pa-
tients [41%]) and B (n ¼ 36 [59%]), depending on
whether they were treated before (cohort A) or after
(cohort B) the decree on national centralization came
into force in 2005.4 Altogether, 59 patients underwent
PE and 1 patient from both cohorts underwent primary
LT due to delayed diagnosis and liver failure.
Based on annual birth rates in Finland,31 the incidence
of BA was 1:18,600. Median annual caseload was 1 (IQR
1 to 2) before and 3.5 (IQR 2 to 4.3) after centralization.
Cohort B patients underwent PE at younger age, had
lower birth weight, and tended to be born earlier and
have lower preoperative bilirubin compared with cohort
A (Table 1). Median age at PE was 64 (IQR 39 to 85)
days.
Liver biopsies at time of PE were available for half (12
of 24) of cohort A and 97% (34 of 35) of cohort B pa-
tients. At PE, histologic features consisted of moderate
to severe fibrosis, portal inflammation, ductal reaction,
and cholestasis (Table 1). Ductal reaction and associated
periportal HCM correlated with age at operation (r ¼
0.679; p < 0.001 and r ¼ 0.463; p ¼ 0.002, respectively)
and degree of fibrosis (r ¼ 0.539; p < 0.001 and r ¼
0.454; p ¼ 0.002, respectively). Portal inflammation
showed no association with baseline characteristics.
Clearance of jaundice
The proportion of patients clearing their jaundice almost
doubled after centralization; 28 of 35 (80%) vs 10 of 24
(42%) (p ¼ 0.005). In total 26% (10 of 38) achieved
COJ later than 3 months after operation, and COJ rate
at 3 months was 65% in cohort B vs 32% in cohort A
(p ¼ 0.028). Median time to COJ showed no difference
between cohorts A and B (3.2 [IQR 1.8 to 6.3] months vs
2.3 [IQR 0.84 to 3.6] months; p ¼ 0.272). At 3 and 6
months after operation, cohort B patients had lower bili-
rubin than cohort A patients (11 [IQR 6.0 to 27] mmol/L
vs 135 [IQR 12 to 283] mmol/L; p < 0.001 and 7.5 [IQR
3.5 to 27] mmol/L vs 182 [IQR 8.0 to 239] mmol/L;
p ¼ 0.008).
In logistic regression, operation after centralization
(OR 5.60; 95% CI 1.76 to 17.9; p ¼ 0.004), high-
grade portal inflammation (OR 3.66; 95% CI 1.35 to
9.97; p ¼ 0.011), and young age at operation (OR
0.98; 95% CI 0.97 to 1.00; p ¼ 0.025) predicted COJ.
In multiple regression, only the effect of portal inflamma-
tion remained significant (OR 3.82; 95% CI 1.23 to 11.9;
p ¼ 0.020).
Variables associated with bilirubin levels at 3 months in
linear regression were operation before centralization
(b ¼ 165; 95% CI 77.6 to 252; p < 0.001), age at PE







(cohort A vs B)
Both cohorts
(n ¼ 61)
Gestational age, wk, median (IQR) 40 (3941) 39 (3840) 0.055 39 (3840)
Gestational weight, g, median (IQR) 3,260 (3,2653,865) 3,264 (2,9283,600) 0.014 3,390 (3,0833,703)
Female, n (%) 14 (56) 19 (53) 1.000 33 (54)
Type of biliary atresia, n (%)
1 1 (4.0) 1 (2.8) 1.000 2 (3.3)
2 2 (8.0) 2 (5.6) 4 (6.6)
3 22 (88) 33 (92) 55 (90)
Age at PE, d, median (IQR) 73 (53101) 54 (2879) 0.016 64 (4085)
Associated malformations, n (%) 9 (36) 13 (36) 1.000 22 (36)
Biliary atresia splenic malformation, n (%) 5 (20) 5 (14) 0.727 10 (16)
Preoperative bilirubin, mmol/L, median (IQR) 186 (146214) 145 (111191) 0.067 169 (132207)
Liver histology at PE, mean (range)
Fibrosis, Metavir, 04 2.75 (3) 2.43 (3) 0.345 2.51 (3)
Portal inflammation, 03 1.58 (3) 2.11 (2) 0.062 1.98 (3)
Cholestasis, mean (range)
Intracellular, 03 1.67 (2) 2.17 (2) 0.078 2.04 (2)
Intracanalicular, 03 2.00 (2) 2.40 (2) 0.095 2.30 (2)
Ductal, 03 1.67 (3) 1.32 (3) 0.394 1.41 (3)
Cytokeratin 7 immunostaining, mean (range)
Periportal hepatocytes, 04 1.17 (1) 1.27 (3) 0.621 1.24 (3)
Proliferating bile ductules, 02 1.50 (2) 1.39 (2) 0.830 1.42 (2)
Results are presented separately for patients treated before (cohort A) and after (cohort B) centralization of biliary atresia management in 2005. Bilirubin and
age at operation data given for patients who underwent PE and not primary liver transplantation (n ¼ 59).
CK7, cytokeratin 7; IQR, interquartile range; PE, portoenterostomy.
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inflammation grade at PE (b ¼ 53.0; 95% CI 101 to
5.41; p ¼ 0.030). Only the effect of centralization
remained statistically significant in multiple regression
(b ¼ 95.0; 95% CI 8.91 to 181; p ¼ 0.031). Other clin-
ical and histologic findings were unrelated with COJ and
bilirubin levels at 3 months (eTable 1).
Native liver survival
Cumulative native liver survival for cohorts A and B were
37.5% (SE 9.6%) and 77.6% (7.5) at 2 years; 37.5%
(9.9) and 70.2% (8.4) at 5 years; and 33.3% (9.6)
and 65.2% (9.2) at 10 years, respectively (Fig. 1). Clear-
ance of jaundice, bilirubin levels at 3 and 6 months post-
operatively, portal inflammation grade at PE, and
centralization were significant predictors of native liver
survival (Fig. 1, Table 2). Among cohort B patients,
BASM and higher periportal HCM at PE predicted
shorter native liver survival, and higher ductal reaction
at PE tended to predict shorter native liver survival
(Table 2).
Bilirubin at 3 months after operation was a better pre-
dictor compared with bilirubin at 6 months and was
therefore chosen for the multivariate analysis. The hazardof death or transplantation was higher if bilirubin was
20 mmol/L at 3 months after operation (hazard ratio
11.0; 95% CI 2.38 to 50.4; p ¼ 0.002), and the effects
of centralization, age, or portal inflammation remained
insignificant.Liver transplantation
During follow-up, 22 patients (11 from both cohorts,
44% and 31%, respectively) underwent LT at age 1.15
(IQR 0.77 to 2.46) years. One patient from both cohorts
underwent primary LT and 20 patients underwent LT af-
ter PE. Of them, the majority (n ¼ 15) received trans-
plants because of liver failure after an unsuccessful PE,
and indications for LT after initial COJ were liver failure
(n ¼ 1), recurrent variceal bleeding (n ¼ 1), recurrent
cholangitis (n ¼ 1), hepatopulmonary syndrome
(n ¼ 1), or refractory ascites (n ¼ 1). Two patients
with BASM died after LT (2 of 5) compared with 17
transplanted patients without BASM surviving until the
end of the follow-up (log-rank test; p ¼ 0.006). Central-
ization, COJ, or baseline characteristics were unrelated
with post-LT survival, which was 91% at 2, 5, and 10
years (Fig. 2). One patient required a retransplantation.
Figure 1. Cumulative native liver survival rates. Cumulative native liver survival according to (A) era of treatment, (B)
clearance of jaundice (COJ) status, (C) plasma bilirubin levels at 3 months after portoenterostomy (PE), and (D) portal
inflammation grade at PE. Subgroups are compared with the log-rank test. Cohort A ¼ 1987 to 2004; cohort B ¼ 2005
to 2016.
50 Hukkinen et al Predictors of Biliary Atresia Outcomes J Am Coll SurgOverall survival
During follow-up, 10 (16%) patients died, more
frequently in cohort A than B (8 of 25 vs 2 of 36;
p ¼ 0.011). All deaths occurred at age younger than
2 years, so the cumulative 2-year survival was equal to
5- and 10-year survival rates, that is 68.0% (9.3) in
cohort A and 93.7% (4.3) in cohort B (p ¼ 0.007,
Table 3). Reasons for death were complications of
advanced liver disease (n ¼ 7), intestinal perforation
(n¼ 1), volvulus (n¼ 1), and heart failure (n¼ 1). Three
patients died on LT waiting list and only 1 of the deceased
patients had cleared his jaundice after PE.
Univariate analyses suggested survival was better among
patients whose bilirubin decreased <20 mmol/L within 3
months of operation (p ¼ 0.001) and who were operatedon after centralization (p¼ 0.007) (Table 3). Neither pre-
dictor remained significant in multivariate analysis.
Follow-up liver histology
Follow-up biopsies were available for 29% (7 of 24) of
cohort A and 86% (30 of 35) of cohort B patients, and
were missing for those aged younger than 1.5 years. Pa-
tients who cleared their jaundice underwent follow-up bi-
opsies at older median age than others (4.73 [IQR 3.13 to
6.25] years vs 0.91 [IQR 0.70 to 1.51] years; p < 0.001).
Fibrosis and periportal HCM increased and ductal re-
action persisted in all patients after PE, and cholestasis
and portal inflammation decreased only after successful
PE and remained unchanged if no COJ was achieved
(Fig. 3, Table 4). Follow-up fibrosis scores correlated
Table 2. Univariate Analysis of 5-Year Kaplan-Meier Native Liver Survival with Cumulative 5-Year Survival Estimates
Univariate
Cohort B 20052016 (n ¼ 35) Both cohorts 19872016 (n ¼ 59)
Patients, n
5-year NL survival,
%, mean (SE) p Value Patients, n
5-year NL survival,
%, mean (SE) p Value
Age at portoenterostomy 0.674 0.392
64 d or younger 22 72.6 (10.6) 32 62.1 (9.1)
Older than 64 d 13 64.6 (14.3) 27 44.2 (10.0)
Biliary atresia splenic malformation 0.023 0.705
No 30 77.0 (8.3) 49 58.0 (7.4)
Yes 5 40.0 (21.9) 10 50.0 (15.8)
Associated malformations 0.311 0.995
No 22 74.3 (9.9) 38 54.9 (8.4)
Yes 13 62.9 (15.0) 21 59.3 (11.3)
Type of biliary atresia 0.278 0.448
1 or 2 3 100.0 6 83.3 (15.2)
3 32 66.9 (9.2) 53 52.9 (7.2)
Bilirubin at 3 mo 0.001 <0.001
<20 mmol/L 22 93.3 (6.4) 29 95.5 (4.4)
20 mmol/L 13 38.5 (13.5) 30 23.3 (7.7)
Bilirubin at 6 mo* 0.013 <0.001
<20 mmol/L 20 92.3 (7.4) 28 91.2 (6.0)
20 mmol/L 13 46.2 (13.8) 24 33.3 (9.6)
Fibrosis, Metavir 0.671 0.543
02 22 70.7 (10.1) 28 58.6 (9.6)
34 12 68.2 (15.4) 18 73.9 (11.3)
Portal inflammation 0.056 0.002
01 7 44.4 (22.2) 13 35.2 (15.2)
23 27 75.1 (8.9) 33 73.6 (8.0)
Intracellular cholestasis 0.327 0.887
01 10 80.0 (12.6) 16 68.8 (11.6)
23 24 64.2 (11.1) 30 60.8 (9.8)
CK7 expression in periportal hepatocytesy 0.035 0.282
01 21 82.0 (9.5) 31 70.9 (8.7)
24 11 48.5 (16.4) 13 49.0 (14.8)
CK7-positive bile ductulus proliferationy 0.070 0.172
01 16 84.6 (10.0) 22 74.5 (9.9)
2 16 56.0 (13.8) 22 54.6 (11.4)
Centralization d 0.014
Before d d 24 37.5 (9.9)
After d d 35 70.2 (8.4)
The p values from the log-rank test are reported. Results presented separately for cohort B and for the whole sample.
*Bilirubin data at 6 months missing for patients who received liver transplant (n ¼ 2) or died (n ¼ 4) before 6 months of PE or in whom bilirubin was not
measured at 6 months (n ¼ 1).
yTwo biopsies were not analyzed for CK7 immunostaining scores.
CK7, cytokeratin 7; NL, native liver.
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and were closely related with periportal HCM, portal
inflammation, and their increase during follow-up
(Fig. 4). In simple regression, follow-up fibrosis score
was associated with biopsy timing after PE (b ¼ 0.09;
95% CI 0.18 to 0.003; p ¼ 0.044), COJ (b ¼ 1.03;95% CI 0.16 to 1.91; p ¼ 0.022), intracellular
(b ¼ 0.49; 95% CI 0.09 to 0.89; p ¼ 0.018), and intra-
canalicular (b ¼ 0.41; 95% CI 0.07 to 0.74; p ¼ 0.018)
cholestasis, ductal reaction (b ¼ 0.86; 95% CI 0.41 to
1.31; p < 0.001), as well as follow-up portal inflammation
(b ¼ 0.99; 95% CI 0.62 to 1.36; p < 0.001) and
Figure 2. Cumulative survival after liver transplantation (LT). Cu-
mulative survival after LT for all transplanted patients from cohorts
A and B (n ¼ 22).
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and their observed change after PE (b ¼ 0.61; 95% CI







64 d or younger 22 95.2 (4.6)
Older than 64 d 13 90.9 (8.7)
Biliary atresia splenic malformation
No 31 96.2 (3.8)
Yes 5 80.0 (17.9
Associated malformations
No 23 95.0 (4.9)
Yes 13 91.7 (8.0)
Bilirubin at 3 mo
<20 mmol/L 22 100
20 mmol/L 13 84.6 (10.0
Bilirubin at 6 mo*
<20 mmol/L 20 100




Results are presented separately for cohort B and for the whole sample. p Values f
undergoing PE and not primary transplantation (n ¼ 59).
*Bilirubin data at 6 months missing for patients who received liver transplantatio
not measured at 6 months (n ¼ 1).0.88 to 0.34; p < 0.001 and b ¼ 0.41; 95% CI
0.23 to 0.59; p< 0.001). In multiple regression (where ab-
solute scores were used instead of their change, and intra-
cellular cholestasis was used to reflect the influence of
cholestasis), only the effect of periportal HCM remained
significant (b ¼ 0.36; 95% CI 0.14 to 0.58; p ¼ 0.002).
Age, histology at PE, time to COJ, or other clinical char-
acteristics were unrelated with follow-up fibrosis.Progression of histologic fibrosis and its predictors
Compared with patients who did not achieve COJ, those
whose bilirubin normalized presented at follow-up with
lower degrees of fibrosis (p ¼ 0.029, Table 4), tendency
toward smaller increase in fibrosis during follow-up
(mean 1.83 [range 2.0] vs 0.79 [range 5.0]; p ¼ 0.057),
and slower fibrosis progression rate (p < 0.001, Fig. 5).
In simple regression, variables associated with fibrosis pro-
gression rate were biopsy timing after PE (b ¼ 0.12; 95%
CI 0.20 to 0.04; p ¼ 0.006), COJ (b ¼ 1.81; 95% CI
1.18 to 2.44; p < 0.001), portal inflammation score at PE
(b ¼ 0.74; 95% CI 1.24 to 0.24; p ¼ 0.005), and
change of portal inflammation during follow-up
(b ¼ 0.73; 95% CI 1.24 to 0.23; p ¼ 0.006). In a
multiple regression model, only the effect of COJ remained
significant (b ¼ 1.60; 95% CI 0.84 to 2.35; p < 0.001).
rvival Estimates
(n ¼ 36) Both cohorts 19872016 (n ¼ 61)
%,
p Value Patients, n
5-y survival, %,



















rom the log-rank test are reported. Bilirubin levels analyzed only for patients
n (n ¼ 2) or died (n ¼ 4) before 6 months of PE or in whom bilirubin was
Figure 3. (AC) Representative native liver histology from the same patient at portoenterostomy (PE) and (DF) 2.4
years after successful PE (200magnification). Portal inflammation (03) reduced from grade 3 to 1 (A, D: hematoxylin
and eosin). Metavir fibrosis stage (04) increased from 2 to 4 (B, E: Herovici stain). Ductal reaction (02, dark brown,
arrow) increased from grade 1 to 2 and hepatocyte-cholangiocyte metaplasia in periportal hepatocytes (04, light
brown, asterisk) from 0 to 4 (C, F: cytokeratin-7 staining).
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This study demonstrates that national centralization of
BA management and standardization of care can consid-
erably improve outcomes, even exceeding those reported
previously.3,7,32,33 Although the incidence of BA in
Finland is equivalent to other European countries,6,21
the annual caseload inevitably remains lower, as Finland’s
population approximates 5.5 million. After centralization
of management, COJ rate increased from 42% to 80%,
showing that excellent PE outcomes can be achieved,Table 4. Liver Histologic Features at Time of Portoenterostom
Histology






Fibrosis, Metavir, 04 2.38 (3) 3.12* (3) 0.009
Portal inflammation, 03 2.27y (2) 1.00 (2) <0.001
Cholestasis
Intracellular, 03 1.96 (2) 0.12z (1) <0.001
Intracanalicular, 03 2.19 (2) 0.08z (2) <0.001
Ductal, 03 1.15 (3) 0.00y (0) <0.001
Cytokeratin 7 immunostaining
Periportal hepatocytes, 04 1.17 (4) 2.04 (2) 0.015
Proliferating bile ductules, 02 1.13 (2) 1.29 (2) 0.356
Results are presented separately for patients who cleared or did not clear thei
33 patients with liver histology available both at baseline and at follow-up. Wilc
operation and at follow-up are reported.
*Mann-Whitney U test p value < 0.05 for the differences observed in histolog
yMann-Whitney U test p value < 0.01 for the differences observed in histologi
zMann-Whitney U test p value < 0.001 for the differences observed in histolo
COJ, clearance of jaundice; PE, portoenterostomy.even with relatively low caseloads, if the treatment process
is rationally planned. Reflecting COJ rates, both native
liver and overall survival estimates improved significantly.
In addition, this study provides novel evidence on BA
liver histopathology and its relation to the clinical out-
comes. High-grade portal inflammation at PE is associ-
ated with improved COJ rates and, consequently, with
slower progression of fibrosis and longer native liver sur-
vival. Periportal HCM was the only predictor of follow-
up fibrosis in multiple regression, and the extent ofy and at Last Follow-Up














2.43 (3) 4.00 (0) 0.026 2.39 (3) 3.30 (3) 0.001
1.71 (2) 1.43 (2) 0.414 2.15 (2) 1.09 (3) <0.001
2.29 (2) 2.00 (2) 0.414 2.03 (2) 0.52 (3) <0.001
2.43 (1) 2.43 (2) 1.000 2.24 (2) 0.58 (3) <0.001
1.67 (3) 2.00 (3) 0.492 1.25 (3) 0.38 (3) 0.002
1.50 (2) 2.67 (2) 0.066 1.23 (2) 2.17 (4) 0.003
1.83 (1) 1.67 (1) 0.564 1.40 (2) 1.23 (2) 0.282
r jaundice after PE (bilirubin <20 vs 20 mmol/L). Data are shown for
oxon signed-rank test p values for the difference between histology scores at
ic scores between COJ and no-COJ subgroups.
c scores between COJ and no-COJ subgroups.
gic scores between COJ and no-COJ subgroups.
Figure 4. Cytokeratin (CK7) expression in periportal hepatocytes, portal inflammation score, and their observed change
between portoenterostomy (PE) and follow-up biopsies according to follow-up Metavir fibrosis scores. The length of the
box represents the interquartile range and the line through the middle of the box the median. Error bars show minimum
and maximum values. Kruskal-Wallis test p < 0.001 for CK7 expression; p ¼ 0.003 for change in CK7 expression;
p < 0.001 for portal inflammation; and p ¼ 0.008 for change in portal inflammation. *Statistically significant difference
when compared with Metavir stage ¼ 4 (p < 0.05).
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gree of fibrosis at PE and its progression during follow-up.
These findings suggest progression of liver damage is
partly regulated by inflammation and ductal reaction.
After failed PE, BA patients die of liver failure within 2
years unless LT is performed.8 The PE success rates typi-
cally vary between 40% and 60%,3,6,7,32 with best out-
comes reported so far from the UK, where BA
treatment has been centralized in 3 hospitals,21 and
from Japan, where BA incidence is remarkably higher
compared with Europe.5 In this study, COJ and 5-year
native liver survival rates almost doubled after centraliza-
tion. Although age at operation decreased simultaneously,
regression models suggested centralization was the most
important factor predicting postoperative bilirubin levels.
In French and Canadian national cohorts, hospitals with
the lowest and highest caseloads achieved similar out-
comes.6,33,34 Our post-centralization results also suggest
that instead of absolute caseload numbers, BA outcomes
are influenced by the quality of each treatment aspect,
including early diagnosis and appropriate surgical tech-
nique, as well as standardized postoperative management
and careful follow-up.25-27 Postoperative steroids can
improve COJ in patients who undergo an early PE,19,25
suggesting children managed after centralization at me-
dian age of 54 days might have particularly benefited
from adjuvant therapy. A combination of steroids, urso-
deoxycholic acid,27 and antibiotics3,26 has been previouslydemonstrated to improve COJ and native liver sur-
vival.35,36 Unfortunately, because the use and dosage of
postoperative medications was variable before centraliza-
tion, their effect could not be controlled for in statistical
analyses.
Bilirubin level at 3 months after operation reflects the
success of PE and has outperformed the prognostic value
of other factors on native liver survival in several large
cohorts.14,37-39 Also, in our patients, bilirubin at 3
months was the best predictor of native liver and overall
survival, and centralization strongly influenced the post-
operative reduction of bilirubin. Patients with BASM
had higher post-LT mortality and shorter native liver
survival in cohort B than others. In addition to
BASM,24,32,33 anatomic subtype of BA6,13,14 and age at
PE3,6,7,13 can influence native liver survival. As splenic
malformations and BA subtypes 1 to 2 each occur in
about 10% of patients,24,38 their predictive value is
evidently limited. Although increased age at operation
relates with shorter transplant-free survival, whether it
limits achievement of COJ remains unclear,3,7,14,38 and
no threshold age beyond which PE would be futile has
been set.10 Although we found bilirubin at 3 months
as the best predictor of LT need, as much as 26% cleared
their jaundice later. Frequent monitoring of clinical sta-
tus and laboratory values are needed to distinguish be-
tween such patients and those who will require LT
during infancy.
Figure 5. Fibrosis progression rate during follow-up in patients who
cleared vs did not clear their jaundice after portoenterostomy (PE).
Patients with Metavir stage 4 at PE (n ¼ 7) are excluded from the
analysis. The length of the box represents the interquartile range
(IQR) and the line through the middle of each box the median. Error
bars show minimum and maximum values. The round dot repre-
sents a value outside the upper quartile þ1.5 times the IQR. Mann-
Whitney U test p value is reported. COJ, clearance of jaundice.
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risk of complications after LT, mortality after primary trans-
plantation in BA is higher compared with LT performed af-
ter PE.6,12,13 In addition, better LT outcomes are achieved in
older children compared with infants,11,40 which supports the
benefit of primary PE unless patients present with liver fail-
ure. As malnutrition and stage of liver disease also influence
LT outcomes,39,40 management of BA in centers with expe-
rienced multidisciplinary teams and a transplantation pro-
gram likely improves patient survival by ensuring
appropriate management, as well as timely listing for LT
when needed.10 Centralization of BA treatment in a hospital
with such services might, in part, explain the improved out-
comes observed in our series.
Viral, autoimmune, or toxic triggers are thought to give
rise to an inflammatory reaction launching destruction of
bile ducts in BA.1,8,41 Different degrees of portal inflamma-
tion were present at diagnosis in virtually all of our patients,
supporting a proinflammatory cause. Interestingly, higher
inflammation scores strongly predicted COJ, longer native
liver survival, and slower fibrosis progression. Portal inflam-
mation reduced only after successful PE, which might have
been facilitated by postoperative adjuvant therapy use after
centralization.19 At PE, most BA patients present with
some degree of liver inflammation,16,41 higher levels of whichhave been reported in cytomegalovirus-associated BA.42 Be-
sides differential viral cause, a predominantly inflammatory
liver histopathology could reflect an earlier and more modifi-
able stage of BA before irreversible progression to a predom-
inantly fibrotic stage, as suggested by gene expression
profiling analyses.41 We found portal inflammation scores
unrelated with age at PE or clinical patient characteristics.
Although our sample is limited by its relatively small size
and some missing biopsies among cohort A patients, the
strong inverse association between inflammation and
improved outcomes appears to be a true biologic
phenomenon.
The main determinant of the course of BA and need for
LT is the progression fibrosis, which pathogenesis is
incompletely understood.22,43,44 In BA and other cholan-
giopathies, a characteristic histologic feature evolving
adjacent to fibrosis is ductal reaction, which refers to he-
patocytes and/or progenitor cells transdifferentiating into
CK7-positive cell lineages, toward either intermediate he-
patocytes or epithelial cells forming immature biliary
ductules.17,43,45 Although mechanisms behind ductal
reaction-driven fibrogenesis remain unclear, worsening
fibrosis correlates closely with increasing ductal reaction
in several acquired liver diseases.45,46 In BA, degree of
biliary proliferation predicts native liver survival and re-
flects the degree of fibrosis at time of PE.15,16 Our results
demonstrate that the extent of ductal reaction and associ-
ated periportal HCM parallel closely the degree of fibrosis
not only at PE but also during the course of BA, suggest-
ing such histopathologic features can promote progressive
fibrosis, even when inflammation resolves after successful
PE. Notably, in multiple regression, periportal HCM was
the only predictor of follow-up fibrosis. In BA animal
models, fibrogenic growth factor signaling from ductal re-
action seems to activate other cell types to produce extra-
cellular matrix.47,48 Further characterization of such
interplay47,49,50 is crucial to understanding how to prevent
progressive liver injury.CONCLUSIONS
Based on more than a decade of follow-up after national
centralization of BA management, outcomes measured as
COJ, native liver survival, and overall survival improved
significantly. Resolution of cholestasis and reduction of
high-grade portal inflammation after PE is associated
with slower fibrosis progression and improved native liver
survival. Despite COJ, liver fibrosis progressed in parallel
with CK7 immunostaining of proliferating bile ductules
and periportal hepatocytes during follow-up, suggesting
expanding biliary fibrosis in BA is closely coupled with
ductal reaction and associated HCM. To what extent
56 Hukkinen et al Predictors of Biliary Atresia Outcomes J Am Coll Surgfibrogenesis and ductal reaction are affected by the initial
inflammatory reaction remains to be elucidated. While
waiting for effective antifibrotic therapies, standardized
multidisciplinary treatment protocols, as well as centrali-
zation of BA management, can postpone the need for
LT and extend patient survival.
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eTable 1. Baseline Characteristics and Liver Biopsy Findings at Portoenterostomy in Relation to Clearance of Jaundice
Characteristic No COJ after PE (n ¼ 21) COJ (n ¼ 38) p Value
Gestational age, wk, median (IQR) 40 (3841) 39 (3840) 0.575
Gestational weight, g, median (IQR) 3,630 (3,3153,825) 3,250 (3,0033,640) 0.020
Type of biliary atresia, n (%)
1 1 (4.7) 1 (2.6) 1.000
2 1 (4.7) 3 (7.9)
3 19 (90) 34 (89)
Age at PE, d, median (IQR) 75 (54100) 56 (2978) 0.013
Associated malformations, n (%) 6 (29) 15 (39) 0.571
Biliary atresia splenic malformation, n (%) 3 (14) 7 (18) 1.000
Preoperative bilirubin, mmol/L, median (IQR) 176 (142195) 159 (110213) 0.322
Liver histology at PE, mean (range)
Fibrosis, Metavir, 04 2.54 (3) 2.45 (3) 0.925
Portal inflammation, 03 1.46 (3) 2.18 (2) 0.008
Cholestasis, mean (range)
Intracellular, 03 1.92 (2) 2.09 (2) 0.533
Intracanalicular, 03 2.15 (2) 2.33 (2) 0.290
Ductal, 03 1.67 (3) 1.33 (3) 0.409
Cytokeratin 7 immunostaining, mean (range)
Periportal hepatocytes, 04 1.33 (2) 1.16 (2) 0.427
Proliferating bile ductules, 02 1.67 (1) 1.31 (2) 0.177
COJ, clearance of jaundice; IQR, interquartile range; PE, portoenterostomy.
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